Get started
Author

Ceren H. Çitirikkaya

Observed names: C Citirikkaya, C H Çitirikkaya, C. Çitirikkaya, Ceren Citirikkaya, Ceren H Çitirikkaya
Observed institution: The Netherlands Cancer Institute
OpenAlex ID: A5021520164
Buparlisib is a brain penetrable pan-PI3K inhibitor
2018 · Mark C. de Gooijer, Ping Zhang, et al. · Scientific Reports · 78
PDF
ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost
2021 · Mark C. de Gooijer, E. Marleen Kemper, et al. · Cell Reports Medicine · 62
PDF
Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis
2022 · Rebeca Uceda-Castro, Andreia S. Margarido, et al. · Cell Reports Medicine · 39
PDF
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461
2018 · Mark C. de Gooijer, Levi C.M. Buil, et al. · Molecular Pharmaceutics · 25
BCRP drives intrinsic chemoresistance in chemotherapy-naïve breast cancer brain metastasis
2023 · Rebeca Uceda-Castro, Andreia S. Margarido, et al. · Science Advances · 19
PDF
ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain
2024 · Aristeidis Lentzas, Mark C. de Gooijer, et al. · Fluids and Barriers of the CNS · 9
The ABCB1/ABCG2 inhibitor elacridar is a more potent pharmacoenhancer compared to tariquidar for treatment of intracranial tumors with small molecule drugs
2022 · O. Van Tellingen, A. Lentzas, et al. · European Journal of Cancer · 3
PDF
Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma
2026 · Mark C. de Gooijer, Daria M. Fedorushkova, et al. · Cellular Oncology · 1
PDF
Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma
2024 · Mark C. de Gooijer, Ping Zhang, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
P10.21.a the Abcb1/abcg2 Inhibitor Elacridar Is a More Potent Pharmacoenhancer Compared to Tariquidar for Treatment of Intracranial Tumors With Small Molecule Drugs
2023 · A Lentzas, M C de Gooijer, et al. · Neuro-Oncology · 1
PDF
P03.11.b Mitotic Enrichment as an Efficient Radiosensitization Strategy for Intracranial Tumors
2023 · M C de Gooijer, H Çolakoğlu, et al. · Neuro-Oncology · 1
PDF
P04.91 ABC-drug efflux transporters at the blood-brain barrier limit the efficacy of treatment against primary and secondary brain tumors
2018 · O van Tellingen, M C de Gooijer, et al. · Neuro-Oncology · 1
Rbio-05. Mitotic Enrichment as an Efficient Radiosensitization Strategy for Intracranial Tumors
2023 · Mark de Gooijer, Hilal Colakoglu, et al. · Neuro-Oncology
PDF
Abstract PO-003: Mitotic enrichment as an efficient radiosensitization strategy
2021 · Mark C. de Gooijer, Paul L.G. Slangen, et al. · Clinical Cancer Research
Ddre-32. Abc Transporters Restrict the Brain Penetration and Intracranial Efficacy of Anticancer Agents Even When Blood-brain Barrier Integrity Is Lost
2020 · Mark C de Gooijer, E Marleen Kemper, et al. · Neuro-Oncology
Exth-72. Continuous Infusion Studies Reveal the Potency of Elacridar to Act as a Pharmaco-enhancer for Treatment of Intracranial Diseases by Inhibiting Abcb1 and Abcg2 at the Blood-brain Barrier
2020 · Olaf van Tellingen, Mark C de Gooijer, et al. · Neuro-Oncology
PDF
Rbio-05. Mitotic Enrichment as an Efficient Strategy to Radiosensitize Glioblastoma
2020 · Mark C de Gooijer, Paul L G Slangen, et al. · Neuro-Oncology
PDF
Works count: 17
Citation count: 240
H-index: 6
I10-index: 5
Year
Topic
Type